title: Introduction to the treatment of lung cancer.
abstract: Lung cancer represents the leading cause of cancer mortality worldwide. Its incidence has declined in men but is increasing in women, assuring that this largely preventable disease will continue to affect millions. In small cell lung cancer, the advent of chemotherapy in the 1970s and continued refinements in the 1980s yielded improved median survivals in patients with both limited disease and extensive disease and improved long-term survival in limited-disease patients. Reinduction chemotherapy was shown in the 1980s to improve survival in patients who had achieved a complete remission to initial chemotherapy, and a consensus subsequently developed regarding standard induction chemotherapy for patients with small cell lung cancer. The prognosis for patients with small cell lung cancer depends largely on delivering the optimal combination chemotherapy to achieve early, maximal cell kill with manageable toxicity. Future challenges include comparing newer combinations and novel schedules of administration with "standard" chemotherapy, optimizing the use of complementary treatment modalities, and refining prognostic factors to better define treatment and improve outcome. In patients with non-small cell lung cancer, single-modality treatment has been compared with combined-modality therapy in numerous randomized trials, with consistent survival benefits accrued by patients in combined-modality treatment arms. The recent availability of novel cytotoxic and cytostatic agents has prompted additional comparisons of new combination-chemotherapy regimens, with or without other treatment modalities, in patients with lung cancer. Questions for the future include defining the most effective chemotherapy to eradicate distant metastases and understanding which modalities offer superior local control.
authors.affiliation: Department of Medical Oncology, University Hospital Rotterdam Dijkzigt, The Netherlands.
authors.forename: T A
authors.initials: TA
authors.lastname: Splinter
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male